Booklet Updates - Myelodysplastic Syndromes
The following drug updates are listed by booklet title. This information is not found in the current version of these booklets, as these treatments were not FDA approved at the time the books were published.
Myelodysplastic Syndromes
and
The MDS Guide: Information for Patients and Caregivers
- In June 2024, the Food and Drug Administration (FDA) approved imetelstat (Rytelo) for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia requiring 4 or more red blood cell units over 8 weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESA).
- In October 2023, the Food and Drug Administration (FDA) expanded the indication of ivosidenib (Tibsovo®) to include the treatment of patients with a susceptible IDH1 mutation as detected by an FDA-approved test in adult patients with relapsed or refractory myelodysplastic syndromes (MDS).
- In August 2023, the Food and Drug Administration (FDA) expanded the indication of luspatercept-aamt (Reblozyl®) to include the treatment of anemia without previous erythropoiesis stimulating agent use (ESA-naïve) in adult patients with very low- to intermediate-risk myelodysplastic syndromes (MDS) who may require regular red blood cell (RBC) transfusions.